A coronavirus vaccine the University of Oxford is developing with AstraZeneca Plc showed promising results in early human testing, a sign of progress in the high-stakes pursuit of a shot to defeat the pathogen.
The vaccine increased levels of both protective neutralizing antibodies and immune T-cells that target the virus, according to the study organizers. The results were published Monday in The Lancet medical journal.
Follow latest updates on coronavirus here
“We are seeing very good immune responses, not just on neutralizing antibodies but of T-cells as well,” said Adrian Hill, head of Oxford’s Jenner Institute, in an interview. “We’re stimulating both arms of the immune system.”
Click here for complete coronavirus coverage
The results will be closely scrutinized as governments around the world seek to end a pandemic that’s killed more than 600,000 people and triggered economic turmoil since erupting earlier this year. Moderna Inc., another front-runner, released results last week from an early-stage test that showed its vaccine raised levels of antibodies that fight the virus.